How firms are overcoming the manufacturing challenge behind monoclonal antibodies
Animal Pharm recently detailed the upcoming groundswell of R&D behind monoclonal antibodies (mAbs) and their pending commercialization. However, one key element of bring mAbs to market is their manufacture. But why is this a challenge for firms? And how are they overcoming it?